VERSAVO+ 100MG/4ML INJ VIAL

About

Versavo+ 100mg/4mL Injection Vial contains bevacizumab, a recombinant humanized monoclonal antibody that specifically targets and binds to vascular endothelial growth factor (VEGF). VEGF is a key signaling protein that plays a critical role in angiogenesis, the process of new blood vessel formation, which is essential for tumor growth and metastasis. By neutralizing VEGF, bevacizumab inhibits the formation of new blood vessels that supply nutrients and oxygen to tumors, thereby starving the tumor and impeding its growth. It also normalizes the existing tumor vasculature, which can improve the delivery of co-administered chemotherapy agents. Versavo+ is used in combination with various chemotherapy regimens for the treatment of several types of advanced or metastatic cancers. Its mechanism of action makes it a cornerstone in targeted cancer therapy, aiming to improve progression-free survival and overall survival in eligible patients by disrupting the tumor's blood supply.

Uses

• Treatment of metastatic colorectal cancer.
• Management of non-small cell lung cancer.
• Treatment of metastatic renal cell carcinoma.
• Management of recurrent glioblastoma.

Directions For Use

Administer as an intravenous infusion over 30-90 minutes, typically every 2-3 weeks, as directed by an oncologist. Dosage is based on body weight.

Benefits

• Inhibits tumor angiogenesis.
• Slows tumor growth and progression.
• Extends progression-free survival.
• Improves overall survival in some cancers.
• Enhances efficacy of chemotherapy.
• Targeted therapy with specific mechanism.

Side Effects

• Hypertension
• Proteinuria
• Fatigue
• Headache
• Diarrhea
• Nausea
• Vomiting
• Bleeding events
• Thromboembolic events
• Wound healing complications
• Gastrointestinal perforation (rare)
• Arterial thromboembolism (rare)

Safety Measures

• Alcohol - No direct interaction; however, alcohol may exacerbate general fatigue or nausea associated with cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm and inhibition of angiogenesis.
• Breastfeeding - Not recommended during breastfeeding; discontinue breastfeeding during treatment and for a period after.
• Liver - Use with caution in patients with severe liver impairment; monitoring may be required.
• Kidney - Use with caution in patients with severe kidney impairment; monitoring may be required.
• Lung - Increased risk of pulmonary hemorrhage in some lung cancer patients; monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.